Full Press Release Details
GAITHERSBURG, Md., April 4, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, will present data on its COVID-19 prototype vaccine and its COVID-Influenza Combination vaccine candidate (CIC) at both the World Vaccine Congress 2023 (WVC) in Washington, DC, April 3 to 6, 2023, and the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Copenhagen, Denmark, April 15 to 18, 2023.
At WVC, Novavax will present data on its COVID-19 prototype vaccine as a booster and its CIC. Novavax will also host an Insights and Tools to Counter Vaccine Hesitancy roundtable on April 4, and participate in a panel discussion on The Future of Safety for New Vaccines on April 5. In addition, Novavax has been named a finalist for the 2023 World Vaccine Congress Vaccine Industry Excellence Awards (ViE) in the Best New Vaccine Technology/Platform Award and Best COVID Vaccine Award categories. Winners will be announced in-person at the ViE Awards ceremony during WVC on April 4.
At ECCMID, the Company will present the CIC data and four poster presentations on its COVID-19 prototype vaccine.
Novavax presentations during WVC:
| Author | Presentation title | Details |
| Dunkle, L | Novavax COVID-19 Vaccine: Latest Booster Data and Clinical Updates | Oral Presentation April 5, 2023 10:10am (EDT) |
| Shinde, V | Update on Novavax Influenza and COVID- Influenza Combination Vaccine | Oral Presentation April 5, 2023 3:25pm (EDT) |
| Fix, J | Safety surveillance for COVID-19 vaccines: challenges in the pandemic and endemic settings | Oral Presentation April 5, 2023 12:10pm (EDT) |
Novavax presentations during ECCMID:
| Author | Presentation title | Details |
| Shinde, V | Immunogenicity of a novel COVID-Influenza Combination (CIC) vaccine assessed with response surface modelling (RSM) | Oral Presentation Abstract #02042 April 16, 2023 8:30am (CEST) |
| Toback, S | Interim analysis of an observer- blinded, randomized phase 3 study to evaluate the safety and immunogenicity of a single booster of the NVX-CoV2373 vaccine in adults previously vaccinated with the BBIBP-CorV vaccine | Poster Presentation Poster #P2698 April 17, 2023 12:00pm (CEST) |
| Marchese, A | Reported pregnancy outcomes across NVX-CoV2373 COVID-19 vaccine primary series and booster dose clinical studies | Poster Presentation Poster #P2521 April 17, 2023 12:00pm (CEST) |
| Marchese, A | Healthcare provider perceptions of current and future uptake of COVID-19 vaccines in Europe and North America | Poster Presentation Poster #P2755 April 17, 2023 12:00pm (CEST) |
| Bennett, C | LATE-BREAKER: Immunogenicity of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine with Matrix-M adjuvant (NVX- CoV2373) in well-controlled vs less well-controlled people living with HIV | Poster Presentation Poster #LB039 April 18, 2023 12:00pm (CEST) |
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. Focused on the world's most urgent health challenges, Novavax is currently evaluating vaccines for COVID-19, influenza, and COVID-19 and influenza combined. Please visit novavax.com and LinkedIn for more information.
The World Vaccine Congress
The World Vaccine Congress is a series of conferences and exhibitions that have grown over 23 years to become the largest vaccine meetings of their kind across the globe. The event format allows for whole-sector topics with hundreds of speakers and covers the complete vaccine value chain, enabling thousands of attendees from science, government, and manufacturers to come together to create ground-breaking progress. More information can be found at https://www.terrapinn.com/conference/world-vaccine-congress-washington/index.stm.
SOURCE Novavax, Inc.
21 %
more press release views with